Ignite Creation Date:
2024-05-06 @ 9:01 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02880046
Status:
UNKNOWN
Last Update Posted:
2016-08-26
First Post:
2016-08-23
Brief Title:
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology Potential Biomarker for Emerging Immunotherapies
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology Potential Biomarker for Emerging Immunotherapies
Status:
UNKNOWN
Status Verified Date:
2016-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
POLYTCANCER
Brief Summary:
Purposes of this study are
Characterization of polyfunctionality of anti-tumor T lymphocytes using in vitro inhibition of PD-1PDL-1 pathway
Study and comparison of polyfunctionality of anti-tumor T lymphocytes in cohorts of patients with melanoma lung cancer and renal carcinoma This cancers are chosen because of use of anti-PD-1 or anti-PDL-1 antibodies
Comparison of this technique with IFN-γ Elispot assay for detection and quantification of anti-tumor T lymphocytes after in vitro blockade of PD-1PDL-1 pathway
Characterization of polyfunctionality of anti-tumor T lymphocytes using in vitro inhibition of PD-1PDL-1 pathway
Study and comparison of polyfunctionality of anti-tumor T lymphocytes in cohorts of patients with melanoma lung cancer and renal carcinoma This cancers are chosen because of use of anti-PD-1 or anti-PDL-1 antibodies
Comparison of this technique with IFN-γ Elispot assay for detection and quantification of anti-tumor T lymphocytes after in vitro blockade of PD-1PDL-1 pathway
Detailed Description:
In this study an immunomonitoring of specific responses of T lymphocytes to tumor-associated antigens based on detection of intracellular cytokines through flow cytometry after stimulation with all-tumor antigens and blockade of PD-1PDL-1 interaction is used Peripheral blood mononuclear cells of patients with cancers are stimulated with 4 telomerase-peptides or peptides overlapping the entire sequence of survivin
This project studies the frequency and role of polyfunctionality of anti-tumor T lymphocytes in cancerology with an in vitro technique detecting polyfunctional T lymphocytes with a better sensitivity based on removal of an inhibitory PD-1PDL-1 pathway It is a flow cytometry protocol with various theoretical advantages in terms of reproducibility and dynamic monitoring of functionality of different sub-populations of polyfunctional anti-tumor T lymphocytes Moreover it allows the study of molecular mechanisms involved in proliferation of polyfunctional anti-tumor T lymphocytes with the possibility to sort sub-populations
The use of all-tumor antigens allows the use of this technique to evaluate the presence and prognostic or predictive value of this biomarker in various cancers
Detection of polyfunctional anti-tumor T lymphocytes can be a biomarker of anti-tumor lymphocytic adaptive immunity and a potential eligibility or efficacy criteria for new immunotherapies such as anti-PD-1 or anti-PDL-1 treatments
This project studies the frequency and role of polyfunctionality of anti-tumor T lymphocytes in cancerology with an in vitro technique detecting polyfunctional T lymphocytes with a better sensitivity based on removal of an inhibitory PD-1PDL-1 pathway It is a flow cytometry protocol with various theoretical advantages in terms of reproducibility and dynamic monitoring of functionality of different sub-populations of polyfunctional anti-tumor T lymphocytes Moreover it allows the study of molecular mechanisms involved in proliferation of polyfunctional anti-tumor T lymphocytes with the possibility to sort sub-populations
The use of all-tumor antigens allows the use of this technique to evaluate the presence and prognostic or predictive value of this biomarker in various cancers
Detection of polyfunctional anti-tumor T lymphocytes can be a biomarker of anti-tumor lymphocytic adaptive immunity and a potential eligibility or efficacy criteria for new immunotherapies such as anti-PD-1 or anti-PDL-1 treatments
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None